What Caused The VERU Stock To Nose Dive On Thursday?
Stock of Veru Inc. (NASDAQ: VERU) fell -55.56% to $6.67 on Thursday following the rejection of its medicine. Which authorization has VERU been unable to secure? The U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) met yesterday to review sabizabulin for Emergency Use Authorization (EUA) in hospitalized moderate to severe COVID-19 patients […]
